Division of Gilead Sciences Inc.
Latest From Cytopia Ltd.
With many on the executive team who worked on the drug previously, Sierra thinks the stalled Phase III compound could be differentiated from Jakafi and others in the myelofibrosis space based on anemia benefit.
Amgen’s unexpected buyout of deCode Genetics means the founder’s expensive philosophy of focusing on pioneering science rather than quick-to-market products finally will pay off for the Icelandic firm’s venture capital backers.
Crunched credit wiped out many biotech firms in 2009, yet some emerged from the wreckage leaner and stronger. How did they do it, asks Dr Sukaina Virji-Jeganathan.
The private Singapore company S*BIO has taken its Janus kinase 2 (JAK2) inhibitor SB1518 into Phase II development for myeloproliferative and haematological malignancies following positive findings in early clinical studies.
- Therapeutic Areas
- Cytopia Pty. Ltd.
- Parent & Subsidiaries
- Gilead Sciences Inc.
- Senior Management
Andrew Macdonald, CEO
Gavan Flower, CFO
Christopher J Burns, PhD, Dir., Research
- Contact Info
Phone: (61) 3 9208 4222
576 Swan St.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.